Gillian (Gill) Dines is a highly accomplished pharmaceutical executive with 30+ years of experience in research, development, approval, and commercialization of new medicines in both “Big Pharma” and as an entrepreneur in the Biotech environment. She has led the successful
development and global approval of medicines and devices in a number of therapeutic areas including neuroscience, oncology, immunology, respiratory and rare diseases.

Before joining Juvenescence she was Senior Vice President and Head of Research and Early Development at Jazz Pharmaceuticals. In this role she led integration and organisational restructuring to build a novel pipeline and capabilities in R&D following the acquisition of GW Pharma where she was Head of R&D Operations. Before her role in GW/Jazz, Gill was VP Head of New Medicines Strategic Planning at UCB and the UK Site Head. In 2008 she was Company Director and Chief Development Officer at RespiVert, a UK based Biotech that delivered clinical phase assets from start-up to acquisition by Centocor Ortho-Biotech (Janssen Pharmaceuticals). Her previous experience covers various leadership roles across all phases of pharmaceutical R&D over a 20-year tenure at GSK.

Gill firmly believes in achieving a healthy and balanced lifestyle including keeping fit, singing in a local choir and spending quality time with family and friends.